Stryker Corporation (NYSE:SYK) – Research analysts at Gabelli lowered their FY2021 earnings per share estimates for shares of Stryker in a research report issued to clients and investors on Thursday. Gabelli analyst J. Tsai now expects that the medical technology company will post earnings per share of $9.45 for the year, down from their prior estimate of $9.50.

Other equities analysts also recently issued reports about the stock. Wells Fargo & Co upped their price target on shares of Stryker from $160.00 to $166.00 in a research note on Friday, October 27th. ValuEngine raised shares of Stryker from a “hold” rating to a “buy” rating in a research note on Tuesday, November 14th. Canaccord Genuity upped their price target on shares of Stryker from $155.00 to $162.00 and gave the stock a “buy” rating in a research note on Friday, October 27th. Stifel Nicolaus upped their price target on shares of Stryker from $158.00 to $168.00 and gave the stock a “buy” rating in a research note on Friday, October 27th. Finally, Cowen set a $166.00 price target on shares of Stryker and gave the stock a “buy” rating in a research note on Sunday, October 29th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and fourteen have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $162.50.

Stryker (NYSE:SYK) traded down $0.89 during midday trading on Monday, hitting $153.51. 1,789,156 shares of the stock were exchanged, compared to its average volume of 1,396,256. Stryker has a 1-year low of $122.01 and a 1-year high of $170.00. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.29 and a quick ratio of 1.59. The firm has a market capitalization of $56,850.00, a P/E ratio of 56.91, a PEG ratio of 2.33 and a beta of 0.70.

Stryker (NYSE:SYK) last announced its earnings results on Tuesday, January 30th. The medical technology company reported $1.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.95 by $0.01. Stryker had a net margin of 8.20% and a return on equity of 24.55%. The company had revenue of $3.47 billion for the quarter, compared to the consensus estimate of $3.42 billion. During the same period in the previous year, the business earned $1.78 EPS. The company’s revenue was up 9.9% on a year-over-year basis.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in SYK. Bahl & Gaynor Inc. lifted its stake in shares of Stryker by 9.4% in the second quarter. Bahl & Gaynor Inc. now owns 697,086 shares of the medical technology company’s stock valued at $83,518,000 after buying an additional 59,838 shares during the period. Bruderman Asset Management LLC bought a new stake in shares of Stryker in the second quarter valued at about $150,000. BlackRock Inc. lifted its stake in shares of Stryker by 5.2% in the second quarter. BlackRock Inc. now owns 23,115,853 shares of the medical technology company’s stock valued at $3,208,017,000 after buying an additional 1,139,082 shares during the period. Amalgamated Bank lifted its stake in shares of Stryker by 58.1% in the second quarter. Amalgamated Bank now owns 39,665 shares of the medical technology company’s stock valued at $5,505,000 after buying an additional 14,572 shares during the period. Finally, BT Investment Management Ltd bought a new stake in shares of Stryker in the second quarter valued at about $237,000. Institutional investors and hedge funds own 74.85% of the company’s stock.

In other Stryker news, VP William E. Berry, Jr. sold 1,306 shares of the company’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $164.42, for a total transaction of $214,732.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Lonny J. Carpenter sold 5,000 shares of the company’s stock in a transaction dated Friday, February 2nd. The shares were sold at an average price of $163.76, for a total transaction of $818,800.00. Following the sale, the insider now owns 94,253 shares of the company’s stock, valued at $15,434,871.28. The disclosure for this sale can be found here. Insiders have sold 13,856 shares of company stock worth $2,270,968 over the last three months. Company insiders own 7.40% of the company’s stock.

The firm also recently announced a quarterly dividend, which was paid on Wednesday, January 31st. Shareholders of record on Friday, December 29th were given a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a yield of 1.22%. This is an increase from Stryker’s previous quarterly dividend of $0.43. The ex-dividend date was Thursday, December 28th. Stryker’s dividend payout ratio is presently 70.15%.

ILLEGAL ACTIVITY NOTICE: “Stryker Corporation Expected to Earn FY2021 Earnings of $9.45 Per Share (SYK)” was first published by Watch List News and is owned by of Watch List News. If you are reading this report on another website, it was illegally copied and reposted in violation of United States and international trademark & copyright laws. The legal version of this report can be read at https://www.watchlistnews.com/stryker-corporation-expected-to-earn-fy2021-earnings-of-9-45-per-share-syk/1848881.html.

Stryker Company Profile

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

Earnings History and Estimates for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.